DNDi, GlaxoSmithKline, and University of Dundee to identify drug candidates to treat leishmaniasis and Chagas disease

Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.

New open source drug discovery project aims to develop mycetoma treatment

Geneva, Rotterdam, Sydney – 6 February 2018
The MycetOS (Mycetoma Open Source) project was launched today by the University of Sydney, Erasmus MC, and DNDi to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.

GHIT R&D Forum

December 8, 2017
Tokyo, Japan
DNDi presented at the event on the NTD Drug Discovery Booster, Chagas disease, and mycetoma.

Drug discovery for leishmaniasis

This book aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania.

Royal Society of Chemistry, November 2017